Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05626270 · ClinicalTrials.gov registry record · NA
Human Factors Testing for OTC Use of the Erchonia® LunulaLaser
A NA study, sponsored by Erchonia Corporation.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT05626270: Completed NA study, sponsored by Erchonia Corporation.
NCT05626270 is a NA study that has completed, run by Erchonia Corporation. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05626270, a NA study, has completed, sponsored by Erchonia Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
Human factors validation testing to assess the intended user's ability to correctly, safely, and effectively set-up, activate and operate the LunulaLaser™ OTC, to administer a treatment to a suitably qualified client, and to understand the information contained in the Erchonia LunulaLaser™ OTC Installation and Proper Use Reference Guide and box labeling.
Primary Outcome
The outcome measure identifies the number of subject users that were defined as a study "pass". A subject user is determined a study 'pass if the subject satisfactorily completes both the device setup and treatment procedure. If the subject user does not satisfactorily complete either one or both of device setup and/or treatment procedure the subject will be determined a study "fail".
Interventions
- DEVICE LunulaLaser OTC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-06-04 |
| Est. Completion | 2022-12-23 |
| Phase | NA |
What the finished NCT05626270 record still lists
NCT05626270 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which LunulaLaser OTC is the first listed.
NCT05626270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05626270 about?
NCT05626270 is a clinical study titled "Human Factors Testing for OTC Use of the Erchonia® LunulaLaser". Human factors validation testing to assess the intended user's ability to correctly, safely, and effectively set-up, activate and operate the LunulaLaser™ OTC, to administer a treatment to a suitably qualified client, and to understand the information contained in the Erchonia LunulaLaser™ OTC Insta...
What is the current status of trial NCT05626270?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2021-06-04. Estimated completion is 2022-12-23.
What interventions are being tested in trial NCT05626270?
The interventions under investigation include: LunulaLaser OTC (DEVICE).
Who is sponsoring clinical trial NCT05626270?
This trial is sponsored by Erchonia Corporation, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05626270's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI